Literature DB >> 21576088

Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.

Elizabeth A Hopper-Borge1, Timothy Churchill, Chelsy Paulose, Emmanuelle Nicolas, Joely D Jacobs, Olivia Ngo, Yehong Kuang, Alex Grinberg, Heiner Westphal, Zhe-Sheng Chen, Andres J Klein-Szanto, Martin G Belinsky, Gary D Kruh.   

Abstract

Recently, we reported that the ATP-binding cassette transporter 10 (ABCC10), also known as multidrug resistance protein 7 (MRP7), is able to confer resistance to a variety of anticancer agents, including taxanes. However, the in vivo functions of the pump have not been determined to any extent. In this study, we generated and analyzed Abcc10(-/-) mice to investigate the ability of Abcc10 to function as an endogenous resistance factor. Mouse embryo fibroblasts derived from Abcc10(-/-) mice were hypersensitive to docetaxel, paclitaxel, vincristine, and cytarabine (Ara-C) and exhibited increased cellular drug accumulation, relative to wild-type controls. Abcc10(-/-) null mice treated with paclitaxel exhibited increased lethality associated with neutropenia and marked bone marrow toxicity. In addition, toxicity in spleen and thymus was evident. These findings indicate that Abcc10 is dispensable for health and viability and that it is an endogenous resistance factor for taxanes, other natural product agents, and nucleoside analogues. This is the first demonstration that an ATP-binding cassette transporter other than P-glycoprotein can affect in vivo tissue sensitivity toward taxanes. ©2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576088      PMCID: PMC3096848          DOI: 10.1158/0008-5472.CAN-10-3623

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  Mechanisms of Taxol resistance related to microtubules.

Authors:  George A Orr; Pascal Verdier-Pinard; Hayley McDaid; Susan Band Horwitz
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 2.  The MRP family of drug efflux pumps.

Authors:  Gary D Kruh; Martin G Belinsky
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

3.  The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice.

Authors:  D R Johnson; R A Finch; Z P Lin; C J Zeiss; A C Sartorelli
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

4.  Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function.

Authors:  Z S Chen; S Aoki; M Komatsu; K Ueda; T Sumizawa; T Furukawa; H Okumura; X Q Ren; M G Belinsky; K Lee; G D Kruh; M Kobayashi; S Akiyama
Journal:  Int J Cancer       Date:  2001-07-01       Impact factor: 7.396

5.  Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily.

Authors:  E Hopper; M G Belinsky; H Zeng; A Tosolini; J R Testa; G D Kruh
Journal:  Cancer Lett       Date:  2001-01-26       Impact factor: 8.679

6.  Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression.

Authors:  J J Yeh; W H Hsu; J J Wang; S T Ho; A Kao
Journal:  Respiration       Date:  2003 Jan-Feb       Impact factor: 3.580

7.  Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel.

Authors:  Elizabeth Hopper-Borge; Zhe-Sheng Chen; Irina Shchaveleva; Martin G Belinsky; Gary D Kruh
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

8.  Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer.

Authors:  J F Chiou; J A Liang; W H Hsu; J J Wang; S T Ho; A Kao
Journal:  Lung       Date:  2003       Impact factor: 2.584

9.  Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10).

Authors:  Zhe-Sheng Chen; Elizabeth Hopper-Borge; Martin G Belinsky; Irina Shchaveleva; Elena Kotova; Gary D Kruh
Journal:  Mol Pharmacol       Date:  2003-02       Impact factor: 4.436

10.  Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.

Authors:  Richard T Penson; Esther Oliva; Steven J Skates; Tina Glyptis; Arlan F Fuller; Annekathryn Goodman; Michael V Seiden
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

View more
  31 in total

Review 1.  The role of transporters in the toxicity of nucleoside and nucleotide analogs.

Authors:  Christopher A Koczor; Rebecca A Torres; William Lewis
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-04-18       Impact factor: 4.481

Review 2.  Multidrug Resistance Proteins (MRPs) and Cancer Therapy.

Authors:  Yun-Kai Zhang; Yi-Jun Wang; Pranav Gupta; Zhe-Sheng Chen
Journal:  AAPS J       Date:  2015-04-04       Impact factor: 4.009

3.  P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer.

Authors:  Tore B Stage; Christina Mortensen; Sehbar Khalaf; Vivien Steffensen; Helen S Hammer; Chenling Xiong; Flemming Nielsen; Oliver Poetz; Åsa Fex Svenningsen; Cristina Rodriguez-Antona; Deanna L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2020-05-23       Impact factor: 6.875

4.  Boosted coupling of ATP hydrolysis to substrate transport upon cooperative estradiol-17-β-D-glucuronide binding in a Drosophila ATP binding cassette type-C transporter.

Authors:  Agnes Karasik; Kaitlyn Victoria Ledwitch; Tamás Arányi; András Váradi; Arthur Roberts; Flóra Szeri
Journal:  FASEB J       Date:  2018-01-04       Impact factor: 5.191

5.  Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study.

Authors:  Rishil J Kathawala; Kamlesh Sodani; Kang Chen; Atish Patel; Alaa H Abuznait; Nagaraju Anreddy; Yue-Li Sun; Amal Kaddoumi; Charles R Ashby; Zhe-Sheng Chen
Journal:  Mol Cancer Ther       Date:  2014-01-15       Impact factor: 6.261

6.  Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

Authors:  Yi-Jun Wang; Rishil J Kathawala; Yun-Kai Zhang; Atish Patel; Priyank Kumar; Suneet Shukla; King Leung Fung; Suresh V Ambudkar; Tanaji T Talele; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2014-06-14       Impact factor: 5.858

7.  Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach.

Authors:  Merrie Mosedale; Yanwei Cai; John Scott Eaddy; Robert W Corty; Manisha Nautiyal; Paul B Watkins; William Valdar
Journal:  Toxicol Sci       Date:  2019-12-01       Impact factor: 4.849

8.  Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7).

Authors:  Ekaterina V Malofeeva; Natalya Domanitskaya; Mariya Gudima; Elizabeth A Hopper-Borge
Journal:  Cancer Res       Date:  2012-10-19       Impact factor: 12.701

9.  Chemotherapy in pregnancy: exploratory study of the effects of paclitaxel on the expression of placental drug transporters.

Authors:  Paul Berveiller; Olivier Mir; Séverine A Degrelle; Vassilis Tsatsaris; Lise Selleret; Jean Guibourdenche; Danièle Evain-Brion; Thierry Fournier; Sophie Gil
Journal:  Invest New Drugs       Date:  2018-10-26       Impact factor: 3.850

10.  PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.

Authors:  Jun-Jiang Chen; Yue-Li Sun; Amit K Tiwari; Zhi-Jie Xiao; Kamlesh Sodani; Dong-Hua Yang; Saraubh G Vispute; Wen-Qi Jiang; Si-Dong Chen; Zhe-Sheng Chen
Journal:  Cancer Sci       Date:  2012-07-06       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.